1UC Stock Overview
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cue Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.62 |
| 52 Week High | US$1.74 |
| 52 Week Low | US$0.31 |
| Beta | 1.51 |
| 1 Month Change | -6.34% |
| 3 Month Change | -55.71% |
| 1 Year Change | -60.00% |
| 3 Year Change | -79.87% |
| 5 Year Change | -97.72% |
| Change since IPO | -93.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1UC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.0% | -1.6% | 0.8% |
| 1Y | -60.0% | -13.5% | 15.0% |
Return vs Industry: 1UC underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 1UC underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| 1UC volatility | |
|---|---|
| 1UC Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 1UC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1UC's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer.
Cue Biopharma, Inc. Fundamentals Summary
| 1UC fundamental statistics | |
|---|---|
| Market cap | €48.60m |
| Earnings (TTM) | -€36.11m |
| Revenue (TTM) | €7.11m |
Is 1UC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1UC income statement (TTM) | |
|---|---|
| Revenue | US$7.99m |
| Cost of Revenue | US$36.30m |
| Gross Profit | -US$28.30m |
| Other Expenses | US$12.28m |
| Earnings | -US$40.58m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -354.20% |
| Net Profit Margin | -507.87% |
| Debt/Equity Ratio | 51.3% |
How did 1UC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 19:37 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cue Biopharma, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Brian Skorney | Baird |
| Zhiqiang Shu | Berenberg |